Rutinib Cream (Ruxolitinib)
Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Description
Composition: Ruxolitinib Phosphate INN 1.5% cream.
Indication: Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Dosage and administration: A thin layer of cream should be applied to the affected areas with BID of up to 20% of body surface area; not to exceed >60 g/week. It should stop using when signs and symptoms (eg, itch, rash, redness) of atopic dermatitis resolve. If signs and symptoms do not improve within 8 weeks, re-examine the patient. Or, as directed by the registered physician.
Use in pregnancy and lactation: There is no data available.
Packing: Each tube contains 30 gm of cream.
Reviews
There are no reviews yet.